Dynamics of the Major Histocompatibility Complex Class I Processing and Presentation Pathway in the Course of Malaria Parasite Development in Human Hepatocytes: Implications for Vaccine Development

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Ma, Jinxia ^a   Trop, Stefanie ^a   Baer, Samantha ^a   Rakhmanaliev, Elian ^a,c   Arany, Zita ^a,d   Dumoulin, Peter ^a   Zhang, Hao ^a   Romano, Julia ^a   Coppens, Isabelle ^a   Levitsky, Victor ^b,d   Levitskaya, Jelena ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Vela Diagnostics Pte Ltd   (Singapore)

^d Roche Glycart   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CIRCUMSPOROZOITE PROTEIN; CYTOKINE; GREEN FLUORESCENT PROTEIN; LYMPHOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MALARIA VACCINE; MICROORGANISM PROTEIN; PEPTIDE; PROTEIN ANKA; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELL STRUCTURE; CELL SURFACE; CONTROLLED STUDY; DEVELOPMENTAL STAGE; EXPERIMENTAL STUDY; GENE EXPRESSION; HOST PARASITE INTERACTION; HUMAN; HUMAN CELL; LIVER CELL; MOLECULAR DYNAMICS; NONHUMAN; PARASITE DEVELOPMENT; PLASMODIUM BERGHEI INFECTION; PROTEIN EXPRESSION; SPOROZOITE; T LYMPHOCYTE ACTIVATION; UPREGULATION; VACCINE PRODUCTION;

CD8-POSITIVE T-LYMPHOCYTES; DNA PRIMERS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, MHC CLASS I; HEPATOCYTES; HUMANS; MALARIA; MALARIA VACCINES; PLASMODIUM; PROTOZOAN PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84884544948     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075321     Document Type: Article

References (63)

1. Vitoria M, Granich R, Gilks CF, Gunneberg C, Hosseini M, et al. (2009) The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. Am J Clin Pathol 131: 844-848. doi:10.1309/AJCP5XHDB1PNAEYT. PubMed: 19461091.
2. Greenwood B, Salisbury D, Hill AV, (2011) Vaccines and global health. Philos Trans R Soc Lond B Biol Sci 366: 2733-2742. doi:10.1098/rstb.2011.0076. PubMed: 21893534.
3. WHO Malaria Policy Advisory Committee and SecretariatAnd Secretariat WM (2012) Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting. Malar J 11: 424. doi:10.1186/1475-2875-11-424. PubMed: 23253143.
4. Crompton PD, Pierce SK, Miller LH, (2010) Advances and challenges in malaria vaccine development. J Clin Invest 120: 4168-4178. doi:10.1172/JCI44423. PubMed: 21123952.
5. Butler NS, Vaughan AM, Harty JT, Kappe SH, (2012) Whole parasite vaccination approaches for prevention of malaria infection. Trends Immunol 33: 247-254. doi:10.1016/j.it.2012.02.001. PubMed: 22405559.
6. Sinnis P, Coppi A, (2007) A long and winding road: the Plasmodium sporozoite's journey in the mammalian host. Parasitol Int 56: 171-178. doi:10.1016/j.parint.2007.04.002. PubMed: 17513164.
7. Hafalla JC, Silvie O, Matuschewski K, (2011) Cell biology and immunology of malaria. Immunol Rev 240: 297-316. doi:10.1111/j.1600-065X.2010.00988.x. PubMed: 21349101.
8. Cockburn IA, Zavala F, Kumar KA, Sano G, Boscardin S, et al. (2007) T cell memory in malaria. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Curr Opin Immunol 19: 424-429. doi:10.1016/j.coi.2007.05.008. PubMed: 17624749.
9. Schwenk RJ, Richie TL, (2011) Protective immunity to pre-erythrocytic stage malaria. Trends Parasitol 27: 306-314. doi:10.1016/j.pt.2011.02.002. PubMed: 21435951.
10. Tse SW, Radtke AJ, Zavala F, (2011) Induction and maintenance of protective CD8+ T cells against malaria liver stages: implications for vaccine development. Mem Inst Oswaldo Cruz 106 (Suppl 1):: 172-178. doi:10.1590/S0074-02762011000900022. PubMed: 21881772.
11. Balam S, Romero JF, Bongfen SE, Guillaume P, Corradin G, (2012) CSP-A Model for In Vivo Presentation of Plasmodium berghei Sporozoite Antigens by Hepatocytes. PLOS ONE 7: e51875. doi:10.1371/journal.pone.0051875. PubMed: 23272182.
12. Bongfen SE, Torgler R, Romero JF, Renia L, Corradin G, (2007) Plasmodium berghei-infected primary hepatocytes process and present the circumsporozoite protein to specific CD8+ T cells in vitro. J Immunol 178: 7054-7063. PubMed: 17513754.
13. Jobe O, Lumsden J, Mueller AK, Williams J, Silva-Rivera H, et al. (2007) Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells. J Infect Dis 196: 599-607. doi:10.1086/519743. PubMed: 17624847.
14. Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic A, Forbes EK, et al. (2011) CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 187: 1347-1357. doi:10.4049/jimmunol.1100302. PubMed: 21715686.
15. Chakravarty S, Cockburn IA, Kuk S, Overstreet MG, Sacci JB, et al. (2007) CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. Nat Med 13: 1035-1041. doi:10.1038/nm1628. PubMed: 17704784.
16. Cockburn IA, Chen YC, Overstreet MG, Lees JR, van Rooijen N, et al. (2010) Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites. PLOS Pathog 6: e1000877. PubMed: 20463809.
17. Cockburn IA, Tse SW, Radtke AJ, Srinivasan P, Chen YC, et al. (2011) Dendritic cells and hepatocytes use distinct pathways to process protective antigen from plasmodium in vivo. PLOS Pathog 7: e1001318. PubMed: 21445239.
18. Hafalla JC, Rai U, Bernal-Rubio D, Rodriguez A, Zavala F, (2007) Efficient development of plasmodium liver stage-specific memory CD8+ T cells during the course of blood-stage malarial infection. J Infect Dis 196: 1827-1835. doi:10.1086/522965. PubMed: 18190264.
19. Chakravarty S, Baldeviano GC, Overstreet MG, Zavala F, (2008) Effector CD8+ T lymphocytes against liver stages of Plasmodium yoelii do not require gamma interferon for antiparasite activity. Infect Immun 76: 3628-3631. doi:10.1128/IAI.00471-08. PubMed: 18519561.
20. Renggli J, Hahne M, Matile H, Betschart B, Tschopp J, et al. (1997) Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-I) or perforin-mediated cytotoxicity. Parasite Immunol 19: 145-148. doi:10.1046/j.1365-3024.1997.d01-190.x. PubMed: 9106820.
21. Belnoue E, Costa FT, Frankenberg T, Vigário AM, Voza T, et al. (2004) Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 172: 2487-2495. PubMed: 14764721.
22. Morrot A, Zavala F, (2004) Effector and memory CD8+ T cells as seen in immunity to malaria. Immunol Rev 201: 291-303. doi:10.1111/j.0105-2896.2004.00175.x. PubMed: 15361248.
23. Rock KL, (1996) A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 17: 131-137. doi:10.1016/0167-5699(96)80605-0. PubMed: 8820271.
24. Rock KL, Goldberg AL, (1999) Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 17: 739-779. doi:10.1146/annurev.immunol.17.1.739. PubMed: 10358773.
25. Sijts A, Zaiss D, Kloetzel PM, (2001) The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design. Curr Mol Med 1: 665-676. doi:10.2174/1566524013363230. PubMed: 11899255.
26. van Endert PM, (1999) Genes regulating MHC class I processing of antigen. Curr Opin Immunol 11: 82-88. doi:10.1016/S0952-7915(99)80015-6. PubMed: 10047538.
27. Yewdell JW, Snyder HL, Bacik I, Antón LC, Deng Y, et al. (1998) TAP-independent delivery of antigenic peptides to the endoplasmic reticulum: therapeutic potential and insights into TAP-dependent antigen processing. J Immunother 21: 127-131. doi:10.1097/00002371-199803000-00006. PubMed: 9551364.
28. Ewen CL, Kane KP, Bleackley RC, (2012) A quarter century of granzymes. Cell Death Differ 19: 28-35. doi:10.1038/cdd.2011.153. PubMed: 22052191.
29. Hoves S, Trapani JA, Voskoboinik I, (2010) The battlefield of perforin/granzyme cell death pathways. J Leukoc Biol 87: 237-243. doi:10.1189/jlb.0909608. PubMed: 19915166.
30. Lopez JA, Brennan AJ, Whisstock JC, Voskoboinik I, Trapani JA, (2012) Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death. Trends Immunol 33: 406-412. doi:10.1016/j.it.2012.04.001. PubMed: 22608996.
31. Voskoboinik I, Dunstone MA, Baran K, Whisstock JC, Trapani JA, (2010) Perforin: structure, function, and role in human immunopathology. Immunol Rev 235: 35-54. PubMed: 20536554.
32. Berridge MJ, (1997) Lymphocyte activation in health and disease. Crit Rev Immunol 17: 155-178. doi:10.1615/CritRevImmunol.v17.i2.30. PubMed: 9094451.
33. Chinnaiyan AM, Dixit VM, (1997) Portrait of an executioner: the molecular mechanism of FAS/APO-1-induced apoptosis. Semin Immunol 9: 69-76. doi:10.1006/smim.1996.0055. PubMed: 9106309.
34. Nagata S, (1996) Apoptosis mediated by the Fas system. Prog Mol Subcell Biol 16: 87-103. doi:10.1007/978-3-642-79850-4_6. PubMed: 8822794.
35. Van Parijs L, Abbas AK, (1996) Role of Fas-mediated cell death in the regulation of immune responses. Curr Opin Immunol 8: 355-361. doi:10.1016/S0952-7915(96)80125-7. PubMed: 8793992.
36. Abdulghani J, El-Deiry WS, (2010) TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 14: 1091-1108. doi:10.1517/14728222.2010.519701. PubMed: 20819019.
37. Gonzalvez F, Ashkenazi A, (2010) New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 29: 4752-4765. doi:10.1038/onc.2010.221. PubMed: 20531300.
38. Sayers TJ, (2011) Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 60: 1173-1180. doi:10.1007/s00262-011-1008-4. PubMed: 21626033.
39. Abele R, Tampé R, (2011) The TAP translocation machinery in adaptive immunity and viral escape mechanisms. Essays Biochem 50: 249-264. doi:10.1042/bse0500249. PubMed: 21967061.
40. Basta S, Bennink JR, (2003) A survival game of hide and seek: cytomegaloviruses and MHC class I antigen presentation pathways. Viral Immunol 16: 231-242. doi:10.1089/088282403322396064. PubMed: 14583141.
41. Früh K, Bartee E, Gouveia K, Mansouri M, (2002) Immune evasion by a novel family of viral PHD/LAP-finger proteins of gamma-2 herpesviruses and poxviruses. Virus Res 88: 55-69. doi:10.1016/S0168-1702(02)00120-X. PubMed: 12297327.
42. Früh K, Gruhler A, Krishna RM, Schoenhals GJ, (1999) A comparison of viral immune escape strategies targeting the MHC class I assembly pathway. Immunol Rev 168: 157-166. doi:10.1111/j.1600-065X.1999.tb01290.x. PubMed: 10399072.
43. Gruhler A, Früh K, (2000) Control of MHC class I traffic from the endoplasmic reticulum by cellular chaperones and viral anti-chaperones. Traffic 1: 306-311. doi:10.1034/j.1600-0854.2000.010403.x. PubMed: 11208115.
44. Kamp W, Berk MB, Visser CJ, Nottet HS, (2000) Mechanisms of HIV-1 to escape from the host immune surveillance. Eur J Clin Invest 30: 740-746. doi:10.1046/j.1365-2362.2000.00697.x. PubMed: 10964167.
45. Lin A, Xu H, Yan W, (2007) Modulation of HLA expression in human cytomegalovirus immune evasion. Cell Mol Immunol 4: 91-98. PubMed: 17484802.
46. Vossen MT, Westerhout EM, Söderberg-Nauclér C, Wiertz EJ, (2002) Viral immune evasion: a masterpiece of evolution. Immunogenetics 54: 527-542. doi:10.1007/s00251-002-0493-1. PubMed: 12439615.
47. Wiertz E, Hill A, Tortorella D, Ploegh H, (1997) Cytomegaloviruses use multiple mechanisms to elude the host immune response. Immunol Lett 57: 213-216. doi:10.1016/S0165-2478(97)00073-4. PubMed: 9232454.
48. Brander C, Suscovich T, Lee Y, Nguyen PT, O'Connor P, et al. (2000) Impaired CTL recognition of cells latently infected with Kaposi's sarcoma-associated herpes virus. J Immunol 165: 2077-2083. PubMed: 10925292.
49. Levitsky V, Masucci MG, (2002) Manipulation of immune responses by Epstein-Barr virus. Virus Res 88: 71-86. doi:10.1016/S0168-1702(02)00121-1. PubMed: 12297328.
50. Ressing ME, Keating SE, van Leeuwen D, Koppers-Lalic D, Pappworth IY, et al. (2005) Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection. J Immunol 174: 6829-6838. PubMed: 15905524.
51. Johnston JB, McFadden G, (2003) Poxvirus immunomodulatory strategies: current perspectives. J Virol 77: 6093-6100. doi:10.1128/JVI.77.11.6093-6100.2003. PubMed: 12743266.
52. Lorenzo ME, Ploegh HL, Tirabassi RS, (2001) Viral immune evasion strategies and the underlying cell biology. Semin Immunol 13: 1-9. doi:10.1006/smim.2000.0290. PubMed: 11289794.
53. Sattabongkot J, Yimamnuaychoke N, Leelaudomlipi S, Rasameesoraj M, Jenwithisuk R, et al. (2006) Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax. Am J Trop Med Hyg 74: 708-715. PubMed: 16687667.
54. Talman AM, Blagborough AM, Sinden RE, (2010) A Plasmodium falciparum strain expressing GFP throughout the parasite's life-cycle. PLOS ONE 5: e9156. doi:10.1371/journal.pone.0009156. PubMed: 20161781.
55. Levitsky V, Zhang QJ, Levitskaya J, Kurilla MG, Masucci MG, (1997) Natural variants of the immunodominant HLA A11-restricted CTL epitope of the EBV nuclear antigen-4 are nonimmunogenic due to intracellular dissociation from MHC class I:peptide complexes. J Immunol 159: 5383-5390. PubMed: 9548478.
56. Levitsky V, Zhang QJ, Levitskaya J, Masucci MG, (1996) The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4. J Exp Med 183: 915-926. doi:10.1084/jem.183.3.915. PubMed: 8642295.
57. Lee T, Luo L, (1999) Mosaic analysis with a repressible cell marker for studies of gene function in neuronal morphogenesis. Neuron 22: 451-461. doi:10.1016/S0896-6273(00)80701-1. PubMed: 10197526.
58. Alto NM, Orth K, (2012) Subversion of cell signaling by pathogens. Cold Spring Harb Perspect Biol 4: a006114. doi:10.1101/cshperspect.a006114. PubMed: 22952390.
59. Singh AP, Buscaglia CA, Wang Q, Levay A, Nussenzweig DR, et al. (2007) Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell 131: 492-504. doi:10.1016/j.cell.2007.09.013. PubMed: 17981117.
60. Coppi A, Pinzon-Ortiz C, Hutter C, Sinnis P, (2005) The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J Exp Med 201: 27-33. doi:10.1084/jem.20040989. PubMed: 15630135.
61. Graewe S, Rankin KE, Lehmann C, Deschermeier C, Hecht L, et al. (2011) Hostile takeover by Plasmodium: reorganization of parasite and host cell membranes during liver stage egress. PLOS Pathog 7: e1002224. PubMed: 21909271.
62. Frevert U, Galinski MR, Hügel FU, Allon N, Schreier H, et al. (1998) Malaria circumsporozoite protein inhibits protein synthesis in mammalian cells. EMBO J 17: 3816-3826. doi:10.1093/emboj/17.14.3816. PubMed: 9669999.
63. Trimnell A, Takagi A, Gupta M, Richie TL, Kappe SH, et al. (2009) Genetically attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of Plasmodium yoelii liver stage-infected hepatocytes. J Immunol 183: 5870-5878. doi:10.4049/jimmunol.0900302. PubMed: 19812194.